Integra LifeSciences price target lowered to $39 from $41 at Truist

Truist lowered the firm’s price target on Integra LifeSciences to $39 from $41 and keeps a Hold rating on the shares. The analyst cites the company’s Q3 earnings miss and guidance cut, stating that while investor expectations were not high coming in, the incremental impacts from the Boston facility driving the miss and the ongoing uncertainty around the resolution of the issues will “keep shares range bound”.